BMK Glycidic Acid (sodium salt) CAS 5449-12-7 Pharmaceutical intermediates
arthritis
1.
2. RA is the chronic inflammatory and systemic auto
immune disease predominantly affecting the joints
and periarticular tissue.
Chronic untreated inflammation may lead to joint
erosion and destruction.
RA is a complex process, involving synovial cell
proliferation and fibrosis, pannus formation and
cartilage and bone erosion.
This process is mediated by an interdependent
network of cytokines, prostanoids and proteolytic
Enzymes.
3. About 1% of the world's population is
afflicted by RA
Prevalence Of 0.75% in India
Most common in women than man
( Female: male ratio of 3:1)
Affecting people between the age of
20-55 years
40% of RA patients are registered as
disabled with in three year of onset
and around 80% are disabled within
20 years.
4. Symptoms of RA includes
Morning stiffness that last for at least 1 hr.
Joint pain with warmth, swelling, tenderness
and stiffness of the joint after resting
Low-grade fever.
Inflammation of small blood vessels can
cause small nodules under the skin, but they
are generally painless
5.
6. • The dominant feature is inflammation,
primary in synovium.
• The synovial membrane in RA becomes
hyperplastic.
• There is an increased number of both type
synoviocytes and is infiltrated with immune
and inflammatory cells: particularly
macrophages, B- and T-lymphocytes, plasma
cells and dendritic cells.
• Increased levels of cytokines are present.
Cytokines play a central role in the
perpetuation of synovial inflammation.
7.
8. NSAIDS
e.g. Etoricoxib, celecoxib, paracetamol etc.
Corticosteroids
e.g. prednisone, prednisolone, methyl
prednisolone
DMARDs
e.g. Methotrexate, Leflunomide
Cytotoxic drug
e.g. Cyclophosphamide